$ETON: Eton Pharma Wins Big With FDA Hypotension Treatment Approval

Date: Tuesday, October 22nd, 2019

Stock(s) mentioned:

Source: 24/7 Wall St. (https://247wallst.com)

Summary: Eton Pharmaceuticals Inc. (NASDAQ: ETON) shares jumped on Tuesday after the firm announced that the U.S. Food and Drug Administration (FDA) has …

Full article address: https://247wallst.com/healthcare-business/2019/10/22/eton-pharma-wins-big-with-fda-hypotension-treatment-approval/

Related News:

$ETON: What Kind Of Investor Owns Most Of Eton Pharmaceuticals, Inc …

$ETON: Eton Pharma up 20% premarket on FDA nod for Biorphen

$HEXO $ETON $GMDA: MKM bearish on Curaleaf and Aurora Cannabis in premarket …

$HEXO $ETON $GMDA: MKM bearish on Curalead and Aurora Cannabis in premarket …

$NBRV $FGEN $ETON $CELC: Nabriva (NBRV) Aims to Resubmit Contepo NDA in Q4

$ACOR $CLDX $ETON $KDMN: Kadmon (KDMN) Completes Enrollment in KD025 Study for cGVHD

$REGN $CLDX $ACOR $ETON: Regeneron Ebola Treatment Shows Promise, Study Stopped Early

$BGNE $EPZM $ACOR $ETON: Epizyme (EPZM) Q2 Loss In Line, Revenues Beat Estimates

$GALT $PTLA $BHC $ETON: Bausch (BHC) Misses on Q2 Earnings & Sales, Raises View

$ETON: What Kind Of Shareholder Appears On The Eton Pharmaceuticals …

$NVS $ETON $BHC $AXGT: Eton’s Ophthalmic Solution Candidate Gets CRL, Shares Fall

Latest News:

$TGT: Target (TGT) Q3 Earnings and Revenues Top Estimates

$SPX $WMT $MRK: Need to Know: Your three-stock survival kit for 2020, says this equity strategist

$TGT $WMT: Target Blasts Q3 Earnings Forecast, Boosts 2019 Guidance: Shares Hit Record High

$EW: Bull of the Day: Edwards Lifesciences (EW)

$MOV $FOSL: Bear of the Day: Fossil (FOSL)

$SCVL $URBN $BOOT $DECK: Urban Outfitters (URBN) Stock Declines on Q3 Earnings Miss

$TMO $PACB $NUVA $ILMN: Pacific Biosciences (PACB) Q3 Loss Wider Than Estimates

$CNX $PSX $MCF $COP: ConocoPhillips Lays Out Plans for Next Decade, Aims $50B FCF

$NMIH: NMI Holdings Shares March Higher, Can It Continue?

$SAH $BLDR $BCC $DK $CLW: 5 Attractive Stocks Post Recent Broker Rating Upgrades

$LOW $HD: Lowe’s earnings top estimates despite revenue shortfall, raises 2019 forcast